Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

Item

http://www.wikidata.org/entity/Q28303809

Q28303809

about

Conjugate vaccines for preventing meningococcal C meningitis and septicaemia Conjugate vaccines for preventing meningococcal C meningitis and septicaemia Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Immune response, antibody persistence, and safety of a single dose of the quadrivalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine in adolescents and adults: results of an open, randomised, controlled study.Meningococcal glycoconjugate vaccines.Meningococcal conjugate vaccines: optimizing global impact.Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.Oral administration of recombinant Neisseria meningitidis PorA genetically fused to H. pylori HpaA antigen increases antibody levels in mouse serum, suggesting that PorA behaves as a putative adjuvant Genetic and antigenic analysis of invasive serogroup Y Neisseria meningitidis isolates collected from 1999 to 2003 in Canada.Meningococcal A, C, Y and W-135 polysaccharide-protein conjugate vaccines.Meningococcal conjugate vaccine in adolescents and children.Update on prevention of meningococcal disease: focus on tetravalent meningococcal conjugate vaccine.Prevalence of factor H-binding protein variants and NadA among meningococcal group B isolates from the United States: implications for the development of a multicomponent group B vaccine Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.The new meningococcal conjugate vaccine. A profile of its safety, efficacy, and indications for use.Experience with MCV-4, a meningococcal, diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135.Immunogenicity and safety of the quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (MenACWY-TT) in 2-10-year-old children: results of an open, randomised, controlled study.A randomized study to assess the immunogenicity, antibody persistence and safety of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in children aged 2-10 years.Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers The cost and public health burden of invasive meningococcal disease outbreaks: a systematic review.Postgenomics of Neisseria meningitidis for vaccines development.Persistence of the immune response after MenACWY-CRM vaccination and response to a booster dose, in adolescents, children and infants Postgenomics of Neisseria meningitidis: an update.Optimizing protection against meningococcal disease.Molecular typing methods for outbreak detection and surveillance of invasive disease caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae, a review Epidemiology and meningococcal serogroup distribution in the United States.Bacterial outer membrane vesicles in disease and preventive medicine.Glycoconjugate vaccines.Evolving meningococcal immunization strategies.Fighting Neisseria meningitidis: past and current vaccination strategies.The practice of travel medicine: guidelines by the Infectious Diseases Society of America.Safety and immunogenicity of a meningococcal quadrivalent conjugate vaccine in five- to eight-year-old Saudi Arabian children previously vaccinated with two doses of a meningococcal quadrivalent polysaccharide vaccine.Immunoglobulin G subclass response to a meningococcal quadrivalent polysaccharide-diphtheria toxoid conjugate vaccine.Using the tetravalent meningococcal polysaccharide-protein conjugate vaccine in the prevention of meningococcal disease.Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae.

P2860

Q24235722-F49DCD88-3123-4336-AB4A-B53D51704BE3 Q24244951-EE93B255-ECD8-491B-9075-36B721D217CE Q26995760-9E6041C6-4ADA-47D7-A414-92B4F9AF4E87 Q34170021-8B782E2D-5932-4114-A6DA-26EB44D6FB93 Q34627685-3BECB4DF-4184-4018-8828-1D2B6733E63A Q35194824-DA164DDF-6194-4BC0-9B3C-EB62805B00E4 Q35547767-0FFDA278-03D2-4224-B39D-36D9C2CAEF83 Q35655927-0318D730-D0BB-45DC-B896-F9EFB0AA14D7 Q35680467-47EEE51C-68B9-40A2-B9AC-9B2E08F21448 Q35887397-66FE75BB-FD63-42DB-872D-E145E9418C5A Q35913820-CCA4047E-DEE7-4721-99D6-B7FCF7B8C995 Q36154043-8EF4F753-186F-4A42-BE05-C26FAC09E379 Q36193437-5F50FC42-CA48-4A3A-9A48-B0A7CB4EFE17 Q36440863-1F79416A-6894-4CC1-8B66-CC6A6204CE04 Q36464572-68641DB7-C9D6-44F0-8E1D-4AA247B709CB Q36530211-80BACC03-468E-4595-92ED-529087193E60 Q36567729-0E546529-411C-4DC5-8CCD-FD65C80D6CAF Q36600323-940B564F-F5BA-4017-A959-C3274AE8F875 Q36781534-29D458B4-078E-47E3-9A7F-8AC76C539E78 Q36849830-85C5BCB4-BF86-4E5C-B7CD-60FFB756EEE8 Q36849834-11454E1F-87AD-4C02-A804-0D76CEC464C2 Q36952074-3B35C6AA-8CCB-4F94-863B-262B680FC864 Q36973781-FD373CDA-2609-4E87-8EB8-89CF103A2451 Q37131083-A4EB114C-A38A-4D3C-9D76-CD24A1E580DE Q37455163-A6BD2970-DF45-4310-9E5F-4205C2AB72E9 Q37678717-85EC42AA-5A2B-4BBE-B4A5-97E86C60D2D9 Q37693513-206C1171-67A3-4553-8C99-67911745CC27 Q37761235-514688B8-09B7-408C-87DD-6D9EA9C3860B Q37820396-9D8F8C8B-00E1-447B-810B-E3D42CC9CEC0 Q38044755-B83DE3D1-84B9-4C66-8F79-6310C9CD48B0 Q38286082-D454F302-4041-49CA-AE49-19C5A030875F Q38829564-8B719B85-9A92-4001-AC49-B7F7687D0B61 Q39067681-6BB26D04-0D30-45AD-9C5D-4CDE780D2B53 Q41589390-264151DC-5E19-4BF4-B200-95F31185A7AC Q41857495-04D59658-CFFF-4672-95CD-2D2C74257615 Q41932534-121B70DA-2FF2-4DE5-A619-870AF6024A53 Q47134798-78138BBE-CEC4-404B-823A-003941BBC8A8

P2860

Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children

Item

http://www.wikidata.org/entity/Q28303809

description

2005 nî lūn-bûn

@nan

2005 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue